rs34939176

Variant summary

Our verdict is Benign. The variant received -9 ACMG points: 0P and 9B. BP2BA1

This summary comes from the ClinGen Evidence Repository: The NM_004360.5(CDH1):c.2164+17dup variant has an allele frequency of 0.1034 (10%, 3634/35146 alleles, 197 homozygotes) in the Latino subpopulation of the gnomAD v2.1.1 cohort (BA1; BP2). Therefore, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BA1, BP2. LINK:https://erepo.genome.network/evrepo/ui/classification/CA8130206/MONDO:0007648/007

Frequency

Genomes: 𝑓 0.031 ( 120 hom., cov: 31)
Exomes 𝑓: 0.039 ( 1300 hom. )

Consequence

CDH1
NM_004360.5 intron

Scores

Not classified

Clinical Significance

Benign reviewed by expert panel B:12

Conservation

PhyloP100: -0.266

Publications

8 publications found
Variant links:
Genes affected
CDH1 (HGNC:1748): (cadherin 1) This gene encodes a classical cadherin of the cadherin superfamily. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed to generate the mature glycoprotein. This calcium-dependent cell-cell adhesion protein is comprised of five extracellular cadherin repeats, a transmembrane region and a highly conserved cytoplasmic tail. Mutations in this gene are correlated with gastric, breast, colorectal, thyroid and ovarian cancer. Loss of function of this gene is thought to contribute to cancer progression by increasing proliferation, invasion, and/or metastasis. The ectodomain of this protein mediates bacterial adhesion to mammalian cells and the cytoplasmic domain is required for internalization. This gene is present in a gene cluster with other members of the cadherin family on chromosome 16. [provided by RefSeq, Nov 2015]
CDH1 Gene-Disease associations (from GenCC):
  • blepharocheilodontic syndrome 1
    Inheritance: AD Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Ambry Genetics, Illumina, Labcorp Genetics (formerly Invitae), G2P
  • CDH1-related diffuse gastric and lobular breast cancer syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, G2P
  • hereditary breast carcinoma
    Inheritance: AD Classification: DEFINITIVE Submitted by: Ambry Genetics
  • hereditary diffuse gastric adenocarcinoma
    Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Ambry Genetics, Orphanet
  • cleft soft palate
    Inheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
  • orofacial cleft 3
    Inheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
  • blepharocheilodontic syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • familial ovarian cancer
    Inheritance: AD Classification: NO_KNOWN Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -9 ACMG points.

BP2
For more information check the summary or visit ClinGen Evidence Repository.
BA1
For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CDH1NM_004360.5 linkc.2164+17dupA intron_variant Intron 13 of 15 ENST00000261769.10 NP_004351.1
CDH1NM_001317184.2 linkc.1981+17dupA intron_variant Intron 12 of 14 NP_001304113.1
CDH1NM_001317185.2 linkc.616+17dupA intron_variant Intron 13 of 15 NP_001304114.1
CDH1NM_001317186.2 linkc.199+17dupA intron_variant Intron 12 of 14 NP_001304115.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CDH1ENST00000261769.10 linkc.2164+15_2164+16insA intron_variant Intron 13 of 15 1 NM_004360.5 ENSP00000261769.4

Frequencies

GnomAD3 genomes
AF:
0.0310
AC:
4720
AN:
152110
Hom.:
117
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.00671
Gnomad AMI
AF:
0.0110
Gnomad AMR
AF:
0.0710
Gnomad ASJ
AF:
0.0309
Gnomad EAS
AF:
0.0749
Gnomad SAS
AF:
0.0581
Gnomad FIN
AF:
0.0202
Gnomad MID
AF:
0.0127
Gnomad NFE
AF:
0.0336
Gnomad OTH
AF:
0.0320
GnomAD2 exomes
AF:
0.0478
AC:
11608
AN:
243006
AF XY:
0.0465
show subpopulations
Gnomad AFR exome
AF:
0.00805
Gnomad AMR exome
AF:
0.104
Gnomad ASJ exome
AF:
0.0249
Gnomad EAS exome
AF:
0.0786
Gnomad FIN exome
AF:
0.0251
Gnomad NFE exome
AF:
0.0320
Gnomad OTH exome
AF:
0.0430
GnomAD4 exome
AF:
0.0387
AC:
53830
AN:
1391720
Hom.:
1300
Cov.:
23
AF XY:
0.0391
AC XY:
27213
AN XY:
696346
show subpopulations
African (AFR)
AF:
0.00614
AC:
197
AN:
32062
American (AMR)
AF:
0.0979
AC:
4362
AN:
44564
Ashkenazi Jewish (ASJ)
AF:
0.0265
AC:
683
AN:
25740
East Asian (EAS)
AF:
0.0753
AC:
2962
AN:
39350
South Asian (SAS)
AF:
0.0608
AC:
5162
AN:
84868
European-Finnish (FIN)
AF:
0.0246
AC:
1174
AN:
47770
Middle Eastern (MID)
AF:
0.0244
AC:
138
AN:
5652
European-Non Finnish (NFE)
AF:
0.0351
AC:
36975
AN:
1053518
Other (OTH)
AF:
0.0374
AC:
2177
AN:
58196
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.494
Heterozygous variant carriers
0
2548
5096
7644
10192
12740
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
1492
2984
4476
5968
7460
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0311
AC:
4731
AN:
152228
Hom.:
120
Cov.:
31
AF XY:
0.0317
AC XY:
2360
AN XY:
74434
show subpopulations
African (AFR)
AF:
0.00669
AC:
278
AN:
41546
American (AMR)
AF:
0.0710
AC:
1085
AN:
15292
Ashkenazi Jewish (ASJ)
AF:
0.0309
AC:
107
AN:
3468
East Asian (EAS)
AF:
0.0741
AC:
384
AN:
5182
South Asian (SAS)
AF:
0.0580
AC:
279
AN:
4814
European-Finnish (FIN)
AF:
0.0202
AC:
214
AN:
10596
Middle Eastern (MID)
AF:
0.0136
AC:
4
AN:
294
European-Non Finnish (NFE)
AF:
0.0336
AC:
2287
AN:
68010
Other (OTH)
AF:
0.0393
AC:
83
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.499
Heterozygous variant carriers
0
231
461
692
922
1153
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
62
124
186
248
310
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0312
Hom.:
14
Bravo
AF:
0.0342
Asia WGS
AF:
0.0850
AC:
296
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:12
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

not specified Benign:6
Genome Diagnostics Laboratory, Amsterdam University Medical Center
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

Genome Diagnostics Laboratory, University Medical Center Utrecht
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

Apr 04, 2016
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Clinical Genetics, Academic Medical Center
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

Mayo Clinic Laboratories, Mayo Clinic
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

Mar 04, 2025
Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Hereditary diffuse gastric adenocarcinoma Benign:2
Jun 14, 2016
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Breast and/or ovarian cancer Benign:1
Apr 22, 2021
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

not provided Benign:1
Mar 03, 2015
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

CDH1-related diffuse gastric and lobular breast cancer syndrome Benign:1
Aug 10, 2023
ClinGen CDH1 Variant Curation Expert Panel
Significance:Benign
Review Status:reviewed by expert panel
Collection Method:curation

The NM_004360.5(CDH1):c.2164+17dup variant has an allele frequency of 0.1034 (10%, 3634/35146 alleles, 197 homozygotes) in the Latino subpopulation of the gnomAD v2.1.1 cohort (BA1; BP2). Therefore, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): BA1, BP2.

Hereditary cancer-predisposing syndrome Benign:1
Mar 31, 2015
Color Diagnostics, LLC DBA Color Health
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
PhyloP100
-0.27
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs34939176; hg19: chr16-68857544; COSMIC: COSV55727825; COSMIC: COSV55727825; API